The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 ends flat ahead of Fed decision; GSK slumps on weak earnings

Wed, 29th Jul 2020 09:04

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* GSK hits 15-week low on profit miss

* Barclays falls as loan loss provisions grow

* Next jumps on posting smaller-than-feared slump in sales

* Consumer, tech stocks weigh on mid-cap index

* FTSE 100 up 0.04%, FTSE 250 down 0.2%
(Updates to close)

By Sagarika Jaisinghani and Susan Mathew

July 29 (Reuters) - The FTSE 100 ended flat on Wednesday as
investors held out for more stimulus from the U.S. Congress and
the Federal Reserve, while GlaxoSmithKline, Barclays and Taylor
Wimpey slid on weak quarterly earnings.

The world's largest vaccine maker, GSK, slumped 3.2%
to hit a 15-week low after missing second-quarter profit
estimates under the effect of coronavirus lockdowns, dragging
the healthcare index down 1.8%.

Kicking off the quarterly earnings season for UK banks,
Barclays set aside a higher-than-expected 1.6 billion
pounds ($2.07 billion) to cover a possible rise in loan losses
due to the COVID-19 pandemic. Its shares fell 6.1%.

But a 7.7% jump for Next Plc helped the blue-chip
FTSE 100 end in positive territory as the retailer
reported a smaller-than-feared slump in second-quarter sales.

The mid-cap FTSE 250 was off 0.2%, weighed by losses
in consumer discretionary, financial and tech-related stocks.

The Fed is expected to sound reassuringly accommodative at
its policy review due at 2 p.m. ET (1800 GMT), followed by Chair
Jerome Powell's press conference, but investors have turned wary
over political wrangling between U.S. Democrats and Republicans
on a coronavirus relief plan.

"Not much will come of (the Fed meeting) in terms of policy.
That said, we think a sober assessment from the Fed or Powell
could challenge risk sentiment," said Mazen Issa, senior FX
strategist at TD Securities.

"With COVID cases ravaging the U.S. and the job market
stalling, there is a risk that Powell sounds more bearish than
dovish."

Uncertainty about global efforts to contain the pandemic
stalled a three-month rally for the FTSE 100 in July. Although
recent economic data has shown a revival in business activity
with the lifting of nationwide lockdowns, traders are concerned
about the damage from another possible shutdown.

Homebuilder Taylor Wimpey Plc shed 8.1% on saying it
expected to complete around 40% fewer homes in 2020.

(Reporting by Sagarika Jaisinghani in Bengaluru; editing by
Uttaresh.V and Kevin Liffey)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.